Trials / Completed
CompletedNCT03418922
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Specified doses will be administered orally on specified days. |
| DRUG | Nivolumab | Specified doses will be administered intravenously on specified days. |
Timeline
- Start date
- 2018-01-16
- Primary completion
- 2022-12-28
- Completion
- 2022-12-28
- First posted
- 2018-02-01
- Last updated
- 2024-06-20
- Results posted
- 2024-06-20
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03418922. Inclusion in this directory is not an endorsement.